Featured Research

from universities, journals, and other organizations

Capturing leukemic stem cells: Major breakthrough in developing new cancer drugs

Date:
March 18, 2014
Source:
Universite de Montreal
Summary:
Researchers recently achieved a significant breakthrough thanks to the laboratory growth of leukemic stem cells, which will speed up the development of new cancer drugs. The scientists involved describe how they succeeded in identifying two new chemical compounds that allow to maintain leukemic stem cells in culture when these are grown outside the body.

Top: Acute myeloid leukemia cells presenting anomalies in standard growth conditions. Below: Acute myeloid leukemia cells preserving their leukemic cell features following in vitro culture with the two chemical molecules referred to in the study cited.
Credit: Image courtesy of Universite de Montreal

The Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal (UdeM), in collaboration with the Maisonneuve-Rosemont Hospital's Quebec Leukemia Cell Bank, recently achieved a significant breakthrough thanks to the laboratory growth of leukemic stem cells, which will speed up the development of new cancer drugs.

In a recent study published in Nature Methods, the scientists involved describe how they succeeded in identifying two new chemical compounds that allow to maintain leukemic stem cells in culture when these are grown outside the body.

This important advance opens the way to the identification of new cancer drugs to fight acute myeloid leukemia, one of the most aggressive forms of blood cancer.

The ability to grow leukemic stem cells in culture is a major breakthrough. The next step is to study the molecular mechanisms that regulate the survival and proliferation of leukemic cells as well as the resistance to cancer drugs.

This study is the work of the "Leucégène" research group. This group is co-directed by Dr. Guy Sauvageau, chief executive officer and principal investigator at IRIC as well as professor in the Department of Medicine at the UdeM; by Dr. Josée Hébert, director of the Quebec Leukemia Cell Bank, hematologist at Maisonneuve-Rosemont Hospital and professor in the Department of Medicine at the UdeM; and by Sébastien Lemieux, principal investigator at IRIC. The first author of the study is Caroline Pabst, a postdoctoral fellow at IRIC and associate of the "Leucégène" research group.

"This research breakthrough demonstrates the advantage of working in a multidisciplinary team like the 'Leucégène' research group," stated Drs. Sauvageau and Hébert. "Access to cells of leukemia patients and to IRIC's state-of-the-art facilities are also key factors in pursuing ground-breaking research."

Background to the study Stem cells located in the bone marrow are responsible for the production of blood cells. Unfortunately, deregulation of those cells often produces disastrous consequences when one of them develops mutations that transform it into a malignant cell called "leukemic." The result is an abnormal proliferation of blood cells and the development of leukemia. Leukemic stem cells are also one of the likely causes of patient relapse because they are especially resistant to cancer treatments.

The major obstacle before this discovery was growing stem cells and keeping them intact in vitro, because they quickly lost their cancer stem cell character. As a result, it was very difficult to effectively study the multiplication of cells that cause leukemia.

To get around that difficulty, the team of researchers studied leukemic stem cells from patients with acute myeloid leukemia, obtained from the Quebec Leukemia Cell Bank. After thousands of tests using various chemicals, they identified two new chemical compounds that, when added to the culture medium, can keep functional human leukemic stem cells alive for at least seven days in vitro.


Story Source:

The above story is based on materials provided by Universite de Montreal. The original article was written by Benjamin Augereau. Note: Materials may be edited for content and length.


Journal Reference:

  1. Caroline Pabst, Jana Krosl, Iman Fares, Geneviève Boucher, Réjean Ruel, Anne Marinier, Sébastien Lemieux, Josée Hébert, Guy Sauvageau. Identification of small molecules that support human leukemia stem cell activity ex vivo. Nature Methods, 2014; DOI: 10.1038/nmeth.2847

Cite This Page:

Universite de Montreal. "Capturing leukemic stem cells: Major breakthrough in developing new cancer drugs." ScienceDaily. ScienceDaily, 18 March 2014. <www.sciencedaily.com/releases/2014/03/140318111321.htm>.
Universite de Montreal. (2014, March 18). Capturing leukemic stem cells: Major breakthrough in developing new cancer drugs. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2014/03/140318111321.htm
Universite de Montreal. "Capturing leukemic stem cells: Major breakthrough in developing new cancer drugs." ScienceDaily. www.sciencedaily.com/releases/2014/03/140318111321.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) — The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) — The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) — The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) — In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins